Associate Staff Member, Alcohol, Tobacco and Other Drug Research Unit, Medical Research Council, Cape Town, South Africa.
|
|
- Megan Casey
- 6 years ago
- Views:
Transcription
1
2 Marie Claire Van Hout, PhD M.Sc International Programme in Addiction Studies (IPAS) M.Sc Health Promotion. School of Health Sciences, Waterford Institute of Technology, Ireland Coordinator, Substance Misuse Research Centre registered on the European Network of Centres for Pharmaco-epidemiology and Pharmaco-vigilance (European Medicines Agency). Associate Staff Member, Alcohol, Tobacco and Other Drug Research Unit, Medical Research Council, Cape Town, South Africa. Visiting Research Fellow, Centre for Public Health, Liverpool John Moore s University, Liverpool, United Kingdom Visiting Research Fellow, Glyndwr University, Wales, United Kingdom
3 Principal Investigator Dr Marie Claire Van Hout Marie Sklodowska Curie Actions-Industry-Academia Partnerships and Pathways (IAPP). Scored Highest in Life Sciences Division 96/100. Commenced 9/13 and funded for 36 months 2.04ml. 6 Partners, 27 Marie Curie Fellows. Expert Advisory Panel with representative experts from the European Medicines Agency, European Monitoring Centre for Drugs and Drug Addiction, Royal Pharmaceutical Society UK and Pharmaceutical Society of South Africa. Registered as EC funded study on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) register of the European Medicines Agency.
4
5
6 CODEMISUSED aimed to explore the nature of codeine use, misuse and dependence in Ireland, United Kingdom and South Africa from perspectives of: National stakeholders Consumers Medical, pharmacy & addiction treatment professionals Addiction treatment patients Internet monitoring of online pharmacies and drug forum activity
7
8 . Data will be used to inform: Manufacture and product formulation Monitoring and surveillance Consumer medicine information, packaging and warning labels Responsible prescribing Pharmacy dispensing, risk management and clinical audit Pharmacy screening and brief interventions Road and workplace safety interventions Internet supply and drug forum monitoring CPD training and E-Learning modules for health professionals Specific clinical and community pharmacy treatment protocols
9 Introduction Codeine, or 3-methylmorphine, is the most commonly consumed opiate worldwide, widely used for its analgesic, antidiarrhoeal and antitussive properties. The main pharmaceutical form is the tablet (60%) but codeine is also available as a capsule, effervescent tablet, syrup, suppository and solution Codeine products may also be marketed for subcutaneous or intramuscular injection. Intravenous use is not advised as it may cause hypotension and grand mal convulsions.
10 Regulatory Controls Uses and formulations of codeine vary across countries as do the laws that limit its supply. In most European countries non prescription products contain between 8 15mg of codeine per tablet, and are marketed as a single ingredient drug or in combination with non-steroidal antiinflammatory drugs such as ibuprofen (e.g. Nurofen Plus ), aspirin, paracetamol, caffeine and buclizine to enhance the synergistic effect of drug compounds. Preparations containing codeine of 30mg and above are typically classified as prescription only medicine.
11
12 Medical guidelines for use Recommended dose is maximum 240mg per day in four divided doses with at least 4 hours intervals between doses. NOT more effective in providing pain relief if the single dose is increased above 60mg. Further dose increase will only cause increased adverse effects. Codeine s opiate effect and risk of development of tolerance within a short timeframe on regular or excessive use contributes to abuse potential..
13 Van Hout, MC. Bergin, M. Foley, M. Rich, E. Rapca, AI. Harris, R. Norman I. (2014) A Scoping Review of Codeine Use, Misuse and Dependence, final report. CODEMISUSED Project European Commission 7 th Framework Programme, EU. Brussels. Misuse of codeine containing preparations Codeine produces less euphoria than morphine but has considerable potential for misuse and dependence if not taken as directed. Misuse of opioid pharmaceuticals such as codeine is emerging as a global public health concern, amid calls for revised scheduling and increased pharmacovigilance. Global shift toward availability of non-prescription codeinecontaining products and promotion of patient selfmanagement. Misuse of over the counter codeine-containing products, particularly combination codeine analgesics, is on the increase in countries where available.
14 Van Hout, MC. Bergin, M. Foley, M. Rich, E. Rapca, AI. Harris, R. Norman I. (2014) A Scoping Review of Codeine Use, Misuse and Dependence, final report. CODEMISUSED Project European Commission 7 th Framework Programme, EU. Brussels. Misuse is defined as: The problematic consumption of codeine where risks and adverse consequences outweigh the benefits, and which includes use of codeine with or without prescription, outside of acceptable medical practice or guidelines, for recreational reasons, when self-medicating, with higher doses and for longer than advisable. Prevalence Difficulties in estimating the scale of misuse centre on codeine product availability in pharmacies and online, and the heterogeneous and hidden nature of misuse and dependent use.
15 Van Hout, MC. Bergin, M. Foley, M. Rich, E. Rapca, AI. Harris, R. Norman I. (2014) A Scoping Review of Codeine Use, Misuse and Dependence, final report. CODEMISUSED Project European Commission 7 th Framework Programme, EU. Brussels. Tolerance and dependence Codeine has an identified abuse potential which centres on its opiate effect and development of tolerance within a short timeframe on regular or excessive use. Risk of tolerance is increased through increasing the dose for therapeutic and non-medical or recreational purposes. Physical dependency and withdrawal symptoms mimic those of morphine and, whilst less severe, include cravings, preoccupation with obtaining and taking codeine, lack of control of consumption despite negative side effects, insomnia, restlessness, runny nose, stomach pains, diarrhoea and chills.
16 Van Hout, MC. Bergin, M. Foley, M. Rich, E. Rapca, AI. Harris, R. Norman I. (2014) A Scoping Review of Codeine Use, Misuse and Dependence, final report. CODEMISUSED Project European Commission 7 th Framework Programme, EU. Brussels. Adverse health consequences of misuse Prolonged use of codeine is strongly associated with depression and dysphoric mood states. Codeine can interact with other medications and substances such as alcohol, leading to respiratory depression and other central nervous system effects. Long term use of combination analgesic products containing ibuprofen and paracetamol can lead to gastric ulcers, gastrointestinal bleeding, hepatotoxicity, hypokalaemia, inflammatory bowel conditions, and profound hypokalaemia associated with a severe myopathy. Dependence occurs often in users with no history of substance use disorders and co-morbidity.
17 Van Hout, MC. Bergin, M. Foley, M. Rich, E. Rapca, AI. Harris, R. Norman I. (2014) A Scoping Review of Codeine Use, Misuse and Dependence, final report. CODEMISUSED Project European Commission 7 th Framework Programme, EU. Brussels. Other related consequences of misuse Impairment (driving and neurological damage). Injury risk ( trauma, fractures and lacerations in falls/accidents). Overdose. Injecting harms such as abscess, necrosis and BBV transmission.
18 Types of Misuse Use based on quantity of consumption. I. users that never exceed the maximum dose; i. users who sometimes consume slightly higher than the recommended dose; ii. users who consume significantly higher doses than recommended. Misuse Characteristics I. exceeding recommended doses and treatment duration; II. III. IV. Van Hout, MC. Bergin, M. Foley, M. Rich, E. Rapca, AI. Harris, R. Norman I. (2014) A Scoping Review of Codeine Use, Misuse and Dependence, final report. CODEMISUSED Project European Commission 7 th Framework Programme, EU. Brussels. becoming dependent on codeine for medical reasons (ie. pain); using codeine to manage opiate withdrawals; using codeine for its euphoric effects; V. tampering with codeine preparations.
19 Who misuses Codeine? - Those who usually started to take codeine for therapeutic use but whose doses rapidly increase following experience of its euphoric effects; this group is aware of their dependence but continue to use it to stave off cravings and avoid withdrawal symptoms and often have limited insight into its dependent properties. - Those, many of whom have worsening pain, use it within recommended limits but use it frequently and regularly to manage their pain and may use it to stave off withdrawal associated headaches; this group is usually unaware of being codeine dependent. - Those who consciously misuse codeine for its euphoric effects. - Problematic heroin users and methadone maintenance patients who use codeine to manage withdrawal symptoms and when heroin and methadone are unavailable. Nielsen S, Cameron J, & Pahoki S. (2010). Over the Counter Codeine Dependence. Victoria, Australia: Turning Point Drug and Alcohol Centre.
20 Van Hout, MC. Bergin, M. Foley, M. Rich, E. Rapca, AI. Harris, R. Norman I. (2014) A Scoping Review of Codeine Use, Misuse and Dependence, final report. CODEMISUSED Project European Commission 7 th Framework Programme, EU. Brussels. Wide ranging profile of individuals who misuse codeine parental medication of children. youth drug users adolescents university students. pharmacy customers. drug treatment patients. psychiatric patients. older people.
21 Van Hout, MC. Bergin, M. Foley, M. Rich, E. Rapca, AI. Harris, R. Norman I. (2014) A Scoping Review of Codeine Use, Misuse and Dependence, final report. CODEMISUSED Project European Commission 7 th Framework Programme, EU. Brussels. The available evidence also suggests that many codeine dependent people regret their dependence and associated work and social problems and also reject a drug identity, seeing themselves different from other illicit drug users because of their continued work and social activity and; because they are reassured about its safety through its legal status and availability over the counter from community pharmacies.
22 Van Hout, MC. Bergin, M. Foley, M. Rich, E. Rapca, AI. Harris, R. Norman I. (2014) A Scoping Review of Codeine Use, Misuse and Dependence, final report. CODEMISUSED Project European Commission 7 th Framework Programme, EU. Brussels. Aberrant Behaviours Doctor hopping Pharmacy shopping Selling prescription codeine Forging prescriptions for codeine Obtaining prescriptions from non-medical sources Repeated episodes of lost and/or stolen prescriptions Aggressively demanding increased dosages of codeine Requesting specific products by name Repeated requests Tampering with codeine formulations
23 . Displacement Patterns between OTC and Prescribed Supply Source: Cooper, R (2013:4) 'I can't be an addict. I am.' Over-the-counter medicine abuse: a qualitative study BMJ Open, doi: /bmjopen
24 Van Hout, MC (2015). Nod and Wave: an Internet study of the codeine intoxication phenomenon. International Journal of Drug Policy. 26 (1), pp Codeine Intoxication: Online user information exchange Dulling of emotional and/or physical pain, opiate withdrawal management and for intoxication. Appeal centres on access via family medicine cabinets, prescribers and over the counter in pharmacies. Oral and rectal use, optimal codeine dose per session 250mg. Online indigenous harm reduction; learning to appreciate codeine s effect via moderated use in optimal settings, avoidance of tolerance by use of informed dosing schedules, cold water extraction of codeine, and using codeine as an alternative to stronger opioids. Dissociation, synaesthesia, and out of body experiences. Potentiating practices (i.e. grapefruit) and using over-the-counter medications (anti histamine, antacids) to improve intoxication experiences and reduce unpleasant side effects.
25 Van Hout, MC (2014). Kitchen Chemistry: A scoping review of the diversionary use of pharmaceuticals for non-medicinal use and home production of drug solutions. Drug Testing and Analysis. 6, 7-8, Types of Formulation Tampering and Home manufacture of drug solutions Cold Water Extraction Methods and Nurofen Plus splicing. Oral misuse of codeine cough syrups (i.e Purple Drank, Lemon Drop) Home-made solutions containing codeine cough mixture with alcohol, benzodiazepines, caffeine, kratom and soft drinks (Kratom Cocktails). Home-made solutions for injecting purposes using over the counter codeine products, with morphine (Braun, Home Bake) or by generation of desomorphine (Russian Magic)
26 Van Hout, MC. Bergin, M. Foley, M. Rich, E. Rapca, AI. Harris, R. Norman I. (2014) A Scoping Review of Codeine Use, Misuse and Dependence, final report. CODEMISUSED Project European Commission 7 th Framework Programme, EU. Brussels.. Treatment of Codeine Dependence Clinical profiles of codeine dependents vary but are over represented by females, those in middle to late age, poly substance users, alcohol users, opioid dependents and those with underlying psychiatric conditions. The literature in relation to treatment and management of codeine misuse lacks specificity to codeine protocols. Poor long term outcomes for codeine dependents at 12 month follow up.
27 Challenges for Policy and Practice: how to ensure the availability of codeine for therapeutic use but minimise the risk of misuse? Complexity of inter-relations between the different pharmacological, social, economic, legal and individual factors which shape patterns of use and misuse. Thin dividing line between therapeutic use and misuse of codeine. Focus of European drug agencies on the problem of heroin and substitution treatment for addiction with the result that codeine misuse is often hidden or overlooked. Unsystematic and poorly integrated drug monitoring systems which make it difficult to know the true extent of the codeine misuse problem and the profile of codeine users which hampers proactive drug policies. Potential use of unregulated internet retail sites to purchase codeine and access networks of codeine users..
28 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Manufacturing Stop manufacturing combination products containing codeine and retail single ingredient tamper proof products. Increase the safety of combination codeine products through including antidotes. For example, preparations containing paracetamol could be sold in combination with an antidote, (for example methionine) so that if the dose of paracetamol is increased to the point at which it is unsafe the liver is protected. Tamperproof preparations should be required and backed by legislation and drug companies provided with incentives to invest in these products.
29 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Manufacturing Bar code individual tablets in a blister pack to allow the providence of tablets to be traced. Manufacture smaller packs of codeine which would give only 3-days supply. Producing smaller packs of 18 tablets would have the additional effect of reducing the problem of accidental stockpiling of the drug, which increases dependence risk. In addition smaller packs would probably push up the purchase cost which may be a deterrent to purchase and so decrease overall consumption.
30 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Manufacturing Dependence producing colour coding tablets and/or a warning logo on all tablets and packets of codeine containing medications. Review the safety of available opioids to identify a single standard preparation that has the maximum safety, to be used in all combination preparations sold over the counter.
31 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Product Information and Public Education Strengthen health warnings on the outside of packs of tablets containing codeine For example This medicine contains codeine to more specific warnings such as Not to be taken by children, pregnant women or breastfeeding mothers. These messages could raise customers awareness of the potential for impairment, addiction and harm, and deter development of unintended misuse and habit forming use.
32 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Product Information and Public Education Increasing the visibility of the names of generic drugs which are included in the combination tablet. Public health campaigns that highlight that anyone can become addicted to codeine. Public health campaigns and national patient information campaigns could be adapted to address the different groups of codeine misusers who require targeted messages and interventions.
33 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Product Information and Public Education Development of a protocol to guide health professionals how to approach and advise members of the public to raise their awareness of the risks of codeine misuse and dependence.
34 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Responsible Prescribing.
35 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Responsible Prescribing Codeine should be a prescription only drug. All codeine formulations being recorded at point of sale together with the patient s name. Codeine and acute pain. Protocol on the Cochrane Library of Systematic Reviews by Moore and colleagues which plans an overview of Cochrane reviews to investigate the efficacy of pain medicines available over the counter in the UK for acute pain, that is, short-term pain of less than 12-weeks duration (aspirin, paracetamol, ibuprofen, diclofenac, naproxen, and other drugs alone, and in combinations with each other, with weak opioids like codeine, or with caffeine). This review should provide guidance for health professionals and the public on self-medication for acute pain, as well as responsible prescribing decisions. Development and testing of patient risk assessment tool or procedure for codeine misuse and dependence.
36 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Responsible Prescribing Codeine and chronic pain. Emerging evidence suggests that people who take opioids for more than a month derive little benefit because of the problem of tolerance which means that patients need to take increasingly high doses. Abuse risk of codeine to be clearly indicated at time of prescription in the prescribing manuals and on prescribing decision computer software. Use of opioid agreements. Discharge of patients from pain clinics and hospital with non-opioid containing medications. Handwritten prescription to avoid repeat prescriptions which can occur almost by default and faxed to a nominated community pharmacy. Prescriptions for codeine preparations should be for a maximum of one week Increased vigilance of doctors and other health professionals to health conditions and iatrogenic cause of psychiatric symptoms associated with codeine use.
37 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Monitoring and Surveillance Monitoring codeine sales and purchases through shared patient records and realtime monitoring. Purchases of over the counter and prescribed medications recorded on the patients own data card. Periodic audits of codeine prescription and dispensing.
38 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Dispensing, Screening and Brief Interventions in Community Pharmacies Dispensing Standards advise that non prescribed codeine products should be dispensed only when single ingredient medicinal products are ineffective, as 'second line' products for treatment of pain and used in accordance with marketing authorisations for short term use (no longer than three days). Health information posters in community pharmacies. Require customers to sign on receipt of codeine preparation to indicate they are aware of its dependence potential. Identify indicators of risk of codeine misuse and dependence in community pharmacy customers. Develop a brief self-screening measure to identify pharmacy customers who misuse codeine.
39
40 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Dispensing, Screening and Brief Interventions in Community Pharmacies Develop and testing a brief intervention modelled on the Very Brief Advice on Smoking Intervention developed by the National Centre for Smoking Cessation and Training (NCSCT)
41 Incorporate codeine related enquiry within pharmacists medication use reviews Strengthen the contribution of community pharmacists to treatment of codeine misuse and dependence through: a) direct referral to primary and secondary care services; and b) delivery of structured treatment programmes Recommendations for Innovation: Safety in the Workplace and on the Road Compulsory urine testing in the workplace. Employee assistance programmes. Driving under the influence of codeine.
42 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Internet Supply of Codeine and Technological Support Regular audit of top ranked Google websites to check accuracy of health information on codeine use and misuse Health warnings as a pop-up feature of Internet shopping sites Investment in m-health
43 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Internet Supply of Codeine and Technological Support Online treatment programmes for codeine dependence Websites in South Africa such as (Turn to Help) and (Codeine Care Project) offer specific online and App based information and support for individuals experiencing misuse and dependence on codeine base products Websites in the UK such as (Over-Count) and Codeine Free Me offer useful support for individuals experiencing codeine dependence.
44 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Treatment Further investigation of psychosocial and psychological interventions for codeine dependence Development and testing of standardised criteria to rate codeine dependence and treatment pathways Further development and testing of mobile phone messaging to support adherence to treatment Specialist codeine treatment clinics.
45 Norman I & Van Hout MC. (2015) Mid term review report: work package 9 - innovation. CODEMISUSED Project European Commission 7th Framework Programme, EU: Brussels. Recommendations for Innovation: Learning Resources and Training for Health Professionals Supervised patient contact experience and multi disciplinary training to support care pathways Motivational interviewing training for all health professionals.
46 Van Hout, MC. Bergin, M. Foley, M. Rich, E. Rapca, AI. Harris, R. Norman I. (2014) A Scoping Review of Codeine Use, Misuse and Dependence, final report. CODEMISUSED Project European Commission 7 th Framework Programme, EU. Brussels. Recommendations for Research prevalence of misuse and dependence, therapeutic and non therapeutic pathways and trajectories to misuse and dependence, risk profiles and characteristics of users, poly pharming practices, adverse health and social consequences, treatment and interventions, and displacement between legitimate pharmacy supply and illicit sourcing.
47 Thanking you, the CODEMISUSED Team. Correspondence: Dr Marie Claire Van Hout - mcvanhout@wit.ie
48 Funding Acknowledgement The research leading to these results has received funding from the European Community's Seventh Framework Programme FP7/ under grant agreement no Thanking you, the CODEMISUSED Team. Correspondence: Dr Marie Claire Van Hout - mcvanhout@wit.ie
Codeine Use, Misuse and Dependence
Codeine Use, Misuse and Dependence 23/08/2015 Marie Claire Van Hout, PhD M.Sc International Programme in Addiction Studies (IPAS) M.Sc Health Promotion. Coordinator, Substance Misuse Research, School of
More informationAssociate Staff Member, Alcohol, Tobacco and Other Drug Research Unit, Medical Research Council, Cape Town, South Africa.
Marie Claire Van Hout, PhD M.Sc International Programme in Addiction Studies (IPAS) M.Sc Health Promotion. School of Health Sciences, Waterford Institute of Technology, Ireland Coordinator, Substance Misuse
More informationNon-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients
Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Pharmaceutical Society of Ireland Version 3 October 2017 Updates made following the enactment
More informationPractice implications and recommendations for managing codeine misuse and dependence
Acta Pharm. 65 (2015) 351 364 DOI: 10.1515/acph-2015-0040 Mini review Practice implications and recommendations for managing codeine misuse and dependence MICHAEL BERGIN 1 IAN NORMAN 2 MICHELLE FOLEY 3
More informationSMMGP SPECIAL INTEREST TRAINING DAY
SMMGP SPECIAL INTEREST TRAINING DAY Problematic use of over-the-counter (OTC) medication: prevalence, evidence and how to manage people with these problems Wednesday 11 th May 2011 Chris Ford SMMGP Clinical
More informationCodeine Misuse and Dependence
Codeine Misuse and Dependence Factsheet for Healthcare Professionals CODEMISUSED is a European Union funded project looking into Use, Misuse and Abuse of Codeine. Research has been undertaking in the Republic
More informationHow much codeine to be addicted
How much codeine to be addicted The Borg System is 100 % How much codeine to be addicted 25-6-2014 Learn what to expect from withdrawal if you become dependent on or addicted to codeine. symptoms of codeine
More informationReview of Controlled Drugs and Substances Act
Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A
More informationTRENDS IN SUBSTANCE USE AND ASSOCIATED HEALTH PROBLEMS
Fact Sheet N 127 August 1996 TRENDS IN SUBSTANCE USE AND ASSOCIATED HEALTH PROBLEMS Psychoactive substance use is an increasing public health concern. Problems associated with this use cover a broad spectrum
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationSubstance use and misuse
An open learning programme for pharmacists and pharmacy technicians Substance use and misuse Educational solutions for the NHS pharmacy workforce DLP 160 Contents iii About CPPE open learning programmes
More informationTable of Contents Interim Report of the OxyContin Task Force, Newfoundland & Labrador, January 30, 2004
OXYCONTIN TASK FORCE INTERIM REPORT January 30, 2004 Submitted to Hon. Elizabeth Marshall, Minister of Health & Community Services, Government of Newfoundland and Labrador Table of Contents INTRODUCTION
More informationDrug Trend Bulletin Issue 13 September 2016.
Issue 13 September 2016. The illicit benzodiazepine market in Scotland Drug trends continually change and normally any new substance would be instantly recognisable as users share their experience and
More informationWhat is the strategy?
What is the strategy? Multi-pronged approaches to reducing the health consequences of opioid use, New York City Northeast Epidemiology Conference Public health approach Track drug use and associated health
More informationMedicines to treat pain in adults. Information for patients and carers
Medicines to treat pain in adults Information for patients and carers It is common to feel some pain after having an operation (surgery), trauma or an infection. Controlling pain is an important part of
More informationWhat is pregabalin? Pregabalin tablets. Pregabalin misuse. National Drug Treatment Centre Research. Administration
What is pregabalin? Pregabalin is a prescription drug used to manage a number of long-term conditions, including epilepsy, neuropathic pain and generalised anxiety disorder. Similar to benzodiazepines,
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationGuideline scope Smoking cessation interventions and services
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Topic NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Smoking cessation interventions and services This guideline
More informationNHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification
NHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) Rationale General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification Aims It is the responsibility of general practitioners
More informationTobacco Free Ireland Action Plan
Tobacco Free Ireland Action Plan Tobacco Free Ireland, the report of the Tobacco Policy Review Group, was endorsed by Government, and published in October 2013. It builds on existing tobacco control policies
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification
More informationYou will be prescribed a preparation in the strength of 1mg/1ml. Methadone, like heroin can also cause a physical dependence.
METHADONE LEAFLET: What is Methadone? Methadone is a synthetic drug, used in the treatment of people who have a physical dependence to opiates, thereby preventing the onset of opiate withdrawal symptoms
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES COMMISSION STAFF WORKING DOCUMENT
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 23.11.2009 SEC(2009) 1621 final COMMISSION STAFF WORKING DOCUMENT Report on the implementation of the Council Recommendation of 2 December 2002 on the prevention
More informationTHE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and
THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and effective. Before any drug is approved for marketing
More informationDrug and Alcohol Policy
Drug and Alcohol Policy Purpose Skillset Pty Ltd ( Skillset ) is committed to providing a safe and healthy work environment, so far as is reasonably practicable in which all workers are treated fairly,
More informationPrescribing drugs of dependence in general practice, Part C
HO O Prescribing drugs of dependence in general practice, Part C Key recommendations and practice points for management of pain with opioid therapy H H HO N CH3 Acute pain Acute pain is an unpleasant sensory
More informationNow available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet
Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE
More informationMethadone Diversion: Why it happens, what the illicit market looks like and the implications
Methadone Diversion: Why it happens, what the illicit market looks like and the implications Paul Duffy & Helen Baldwin Centre for Public Health Liverpool John Moores University Methadone provision and
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification
More informationDiversion, misuse and trafficking of methadone and buprenorphine: Impact on recovery
Diversion, misuse and trafficking of methadone and buprenorphine: Impact on recovery Hannu Alho, Ph.D., M.D. Professor of Addiction Medicine, University of Helsinki Research Professor, National Institute
More information2004-L SEPTEMBER
BULLETIN INTELLIGENCE Buprenorphine: Potential for Abuse Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III
More informationHow much codeine can you drink
Search... How much codeine can you drink 23-2-2018 There are other effects of Purple Drank abuse that are an overdose of codeine when abusing Purple Drank, rehab program can be the last one you ever. GO
More informationHarmonization effort for OTC monograph in Taiwan. Ms. Hsueh-Yung (Mary) Tai Deputy Director, Division of Medical Product, Taiwan FDA
Harmonization effort for OTC monograph in Taiwan Ms. Hsueh-Yung (Mary) Tai Deputy Director, Division of Medical Product, Taiwan FDA Outline Background OTC drug registration OTC monographs Future directions
More informationReferral to the Women s Alcohol and Drug Service (WADS) Procedure
Procedure Referral to the Women s Alcohol and Drug Service (WADS) Procedure. Purpose The following document describes criteria for the referral to Women s Alcohol and Drug Service (WADS) and how a referral
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More informationTake Home Naloxone elearning Module Script
elearning Module Script Slide 1-3 Review the outline and the plan for the presentation. Slide 4 We do accept the cynicism of this poster. Slide 5 Read from the slide the definition of Harm Reduction Slide
More informationThe Art of being Human
Science - Year 6 Animals including Humans Block 6AH The Art of being Human Session 6 Resource pack Original resource copyright Hamilton Trust, who give permission for it to be adapted as wished by individual
More informationStandard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care)
Standard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care) Preamble This Standard establishes the standards of practice and ethical requirements of all physicians
More informationThe Society has considered the proposals contained in the consultation document and makes the following principal comments:
Tobacco Consultation Department of Health Room 712 Wellington House 133-135 Waterloo Road London SE1 8UG Mark Nelson Chair of the Practice Committee Pharmaceutical Society of Northern Ireland 73 University
More informationDraft Guidelines on the Sale and Supply of Non- Prescription Medicinal Products from a Retail Pharmacy Business
Draft Guidelines on the Sale and Supply of Non- Prescription Medicinal Products from a Retail Pharmacy Business To facilitate compliance with Regulations 5(1)(d), 5(1)(h) and 10 of the Regulation of Retail
More informationSubstance Misuse in Older People
Substance Misuse in Older People Dr Tony Rao Consultant Old Age Psychiatrist, SLAM NHS Foundation Trust Visiting Researcher, Institute of Psychiatry, Neurology and Neuroscience Chair of Substance Misuse
More informationPOLICY DOCUMENT. CG/pain management in opioid dependency/03/15. Associate Director of Pharmacy
POLICY DOCUMENT Document Title Reference Number PRESCRIBING FOR PAIN MANAGEMENT IN OPIOID DEPENDENT CLIENTS CG/pain management in opioid dependency/03/15 Policy Type Clinical Guideline Electronic File/Location
More informationA LOOK AT ABUSE-DETERRENT OPIOIDS
JULY 2017 Drugs Under Review ICER s report reviewed evidence on ten abuse-deterrent formulations (ADF) of opioids. Nine of the drugs were extended release (ER) opioids, and one was immediate release (IR).
More informationACCESS TO NON-PRESCRIPTION MEDICINES THE KEY ROLE OF PHARMACY IN SELF-CARE
ACCESS TO NON-PRESCRIPTION MEDICINES THE KEY ROLE OF PHARMACY IN SELF-CARE GIRP Position Paper 1. Background Non-prescription medicines (NPMs), also referred to as Over-the-Counter medicines (OTCs), are
More informationGuidance For The Use Of Naltrexone In The Maintenance Of Abstinence in Formerly Opioid Dependent Adults By Clinicians Working Within NHS Grampian
Title: Identifier: Guidance For The Use Of Naltrexone In The Maintenance Of Abstinence in Formerly Opioid Dependent Adults By Clinicians Working Within NHS Grampian NHSG/Guide/NHSG_NaltexMA_885 Replaces:
More informationFact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII
Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication
More informationWorkplace Drug and Alcohol Policy
Workplace Drug and Alcohol Policy January 2017 This Drug and Alcohol Policy is intended for and includes but is not limited to all Students, Contractors and all others either directly or indirectly engaged
More informationPUBLIC CONSULTATION DOCUMENT
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Directorate C Public Health and Risk Assessment POSSIBLE REVISION OF THE TOBACCO PRODUCTS DIRECTIVE 2001/37/EC PUBLIC CONSULTATION DOCUMENT
More informationINTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D
INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D SIXTY-THIRD REGULAR SESSION April 25-27, 2018 México D.F., México OEA/Ser.L/XIV.2.63 CICAD/doc.2385/18 25 April 2018 Original: English THE OPIOID
More informationAnnex II. Scientific conclusions. and detailed explanation of the scientific grounds for the differences. from the PRAC recommendation
Annex II Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 34 Scientific conclusions and detailed explanation of the scientific
More informationSafe Prescribing of Drugs with Potential for Misuse/Diversion
College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines
More informationGOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE
POSITION PAPER GOVERNMENT S ROLE IN ADDRESSING PRESCRIPTION DRUG ABUSE Governments across Canada are concerned about the abuse of prescription drugs, with recent policy discussions focused on mitigating
More informationThe facts about codeine
The facts about codeine AMA backs the independence of the TGA SPECIAL EDITION OCTOBER 2017 SPECIAL EDITION AUSTRALIAN MEDICINE - CODEINE: PRESCRIPTION ONLY - SPECIAL EDITION 1 TGA s independent ruling
More informationniap Terms and Definitions
Our topic today is about analgesics. niap General concept: pain brings patients to the Doctors at the same time. Fear from the pain can keep the patient from going to the Doctors at appropriate time. We
More informationFOUR REASONS CODEINE SHOULD BE S4 BUT GUILD DISAGREES
Page 1 of 9 MENU OFFICIAL PUBLICATION OF NEWS FOUR REASONS CODEINE SHOULD BE S4 BUT GUILD DISAGREES MEGAN HAGGAN 29/06/2016 SHARE ON: Page 2 of 9 A pain specialist and researcher says there s no evidence
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Methadone and buprenorphine for the management of opioid dependence
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Appraisal Methadone and buprenorphine for the management of opioid dependence Comments received from Consultees and Commentators on the draft scope
More informationInternational Drug Control Conventions. Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
18 October 2016 International Drug Control Conventions Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol Convention on Psychotropic Substances of 1971 United Nations Convention
More informationMaxilief Effervescent Tablets
Package Leaflet: Information for the user Maxilief Effervescent Tablets Paracetamol Codeine Phosphate Hemihydrate Caffeine 500mg 8mg 30mg Read all of this leaflet carefully before you start taking this
More informationGuidelines for implementation of Article 14
Guidelines for implementation of Article 14 Demand reduction measures concerning tobacco dependence and cessation Adopted by the Conference of the Parties at its fourth session (decision FCTC/COP4(8))
More informationOCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES
TITLE 16 CHAPTER 10 PART 14 OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES 16.10.14.1 ISSUING AGENCY: New
More informationBuilding a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine
Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine Scott M. Gagnon, MPP, PS-C Director, AdCare Educational Institute of Maine, Inc. Co-Chair, Prevention & Harm
More informationReferral to the Women s Alcohol and Drug Service (WADS) Procedure
1. Purpose The following document describes criteria for the referral to Women s Alcohol and Drug Service (WADS) and how a referral is taken and processed. This includes the referral for clinical care
More informationBrief History of Methadone Maintenance Treatment
METHADONE Brief History of Methadone Maintenance Treatment Methadone maintenance treatment was on the cusp of the social revolution in the sixties. Doctors and public health workers had concluded what
More informationColorado State Board of Medical Examiners Policy
POLICY NUMBER: 10-14 Title: Guidelines for the Use of Controlled Substances for the Treatment of Pain Date Issued: May 16, 1996 Date(s) Revised: November 18, 2004 Reference: 12-36-117, C.R.S. Purpose:
More informationFDA s Response to the Opioid Crisis and the FDA Safe Use Initiative
FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative Scott K. Winiecki, MD Professional Affairs and Stakeholder Engagement Staff (PASES) Center For Drug Evaluation and Research (CDER) U.S.
More informationPrescribing Framework for Naltrexone in Alcohol Relapse Prevention
Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP s Name:... Communication We agree to treat this patient
More informationPrepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
More informationInformation & statistics related to alcohol & drug misuse and community pharmacybased brief advice & intervention
Information & statistics related to alcohol & drug misuse and community pharmacybased brief advice & intervention 1 INTRODUCTION Alcohol and Drug Misuse and their related harms cost our society hundreds
More informationAlcohol, Tobacco and Other Drugs Minimum Standard. April 2015
Alcohol, Tobacco and Other Drugs Minimum Standard April 2015 Contents 1 Executive Summary... 2 2 More Information... 2 3 Using this Standard... 2 4 Standard Provisions... 2 4.1 Legislative Requirements...
More informationDose codeine for cough
Dose codeine for cough 2-11-2013 Find patient medical information for Codeine Antitussive Cough Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings. 27-2- 2018 Detailed
More informationHow to change the legal classification of a medicine in New Zealand
How to change the legal classification of a medicine in New Zealand Guidance document Medsafe October 2017 Page 1 of 15 Contents Purpose and scope... 3 Definitions... 3 Background and legislative context...
More informationWHO Framework Convention on Tobacco Control
WHO Framework Convention on Tobacco Control When WHO was established in 1948, its Member States incorporated the power to negotiate treaties into its Constitution. This power remained dormant until 1996,
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationINFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine
INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine The purpose of this agreement is to give you information about the medications you will be taking for
More informationWithin the Scope of Practice/Role of _X APRN RN LPN CNA ADVISORY OPINION PAIN MANAGEMENT GUIDELIINES
Wyoming State Board of Nursing 130 Hobbs Avenue, Suite B Cheyenne, WY 82002 Phone (307) 777-7601 Fax (307) 777-3519 E-Mail: wsbn-info-licensing@wyo.gov Home Page: https://nursing-online.state.wy.us/ OPINION:
More informationWorkplace Drug and Alcohol Policy
1. Aim Workplace Drug and Alcohol Policy 1.1 Indigenous Consumer Assistance Network Ltd ( ICAN ) is committed to providing a safe and healthy work environment in which all workers are treated fairly, with
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationPOSSIBLE REVISION OF THE TOBACCO PRODUCTS DIRECTIVE 2001/37/EC PUBLIC CONSULTATION DOCUMENT
POSSIBLE REVISION OF THE TOBACCO PRODUCTS DIRECTIVE 2001/37/EC DG SANCO 2010 PUBLIC CONSULTATION DOCUMENT Answer given by the General Direction of Public Health of the Spanish Ministry of Health and Social
More informationPREVENTION. Carroll County Health Department. Bureau of Prevention, Wellness and Recovery
PREVENTION Carroll County Health Department Bureau of Prevention, Wellness and Recovery What is Prevention? Prevention is the promotion of constructive lifestyles and norms that discourage drug abuse.
More informationFrom Wikipedia, the free encyclopedia
1 of 6 11/24/2010 11:43 PM From Wikipedia, the free encyclopedia The regulation of therapeutic goods, that is drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United
More informationRead all of this leaflet carefully because it contains important information for you.
Nurofen Plus Tablets Ibuprofen 200mg, Codeine Phosphate Hemihydrate 12.8mg ADVANCED DUAL ACTION FOR POWERFUL RELIEF Read all of this leaflet carefully because it contains important information for you.
More informationCalifornia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationDemerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subsection: Analgesics and Opioids Original Policy Date: May 8, 2015 Subject: Meperidine Page: 1 of 5 Last
More informationAppearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse
Opening Statement Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse Dr. Chris Simpson, President-elect
More informationROLE OF HEALTH CARE PROVIDERS IN THE MANAGEMENT OF ALCOHOL AND DRUG USE RELATED PROBLEMS
ROLE OF HEALTH CARE PROVIDERS IN THE MANAGEMENT OF ALCOHOL AND DRUG USE RELATED PROBLEMS Dr. Anita Rao? ASK SCREEN Refer HELP T T Ranganathan Clinical Research Foundation TTK Hospital IV Main Road, Indira
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationPain Management for Adult sickle cell disease patients: Information for patients, relatives and carers
Pain Management for Adult sickle cell disease patients: Information for patients, relatives and carers Why you should read this leaflet This leaflet will give you the information necessary to manage your
More information25/04/2017. To ensure that the Rx meets CPSS standards. To provide patient-centered, individualized care. To safely dispense the patient s medication
To ensure that the Rx meets CPSS standards To provide patient-centered, individualized care To safely dispense the patient s medication To assess for clinical stability and progress in treatment Kirsty
More informationOPIOIDS IN AMERICA. A complex crisis. A comprehensive response.
OPIOIDS IN AMERICA A complex crisis. A comprehensive response. Prescription opioids play a critical role in helping millions of people effectively manage chronic pain. But for some, opioid use has become
More informationKANSAS Kansas State Board of Healing Arts. Source: Kansas State Board of Healing Arts. Approved: October 17, 1998
KANSAS Kansas State Board of Healing Arts Source: Kansas State Board of Healing Arts Approved: October 17, 1998 GUIDELINES FOR THE USE OF CONTROLLED SUBSTANCES FOR THE TREATMENT OF PAIN Section 1: Preamble
More informationNRT Voucher redemption scheme service specification
NRT Voucher redemption scheme service specification Updated March 2016 Review date March 2018 Page 1 of 7 1. Introduction The NRT voucher scheme is for NHS Fife stop smoking advisors who have been deemed
More informationAlcohol Health Alliance UK response to the Chief Medical Officer s Alcohol Guidelines Review. March 2016
Alcohol Health Alliance UK response to the Chief Medical Officer s Alcohol Guidelines Review. March 2016 The Alcohol Health Alliance UK (AHA UK) welcomes the opportunity to comment on the clarity and practicality
More informationVirginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationConsumer Labelling of alcoholic beverages A review of practices in Europe
Consumer Labelling of alcoholic beverages A review of practices in Europe European Alcohol and Health Forum, Brussels 8. April 2011 Walter Farke (MPH) Deutsches Institut für Sucht- und Präventionsforschung
More informationNBPDP Drug Utilization Review Process Update
Bulletin # 802 December 1, 2010 NBPDP Drug Utilization Review Process Update The New Brunswick Prescription Drug Program (NBPDP) employs a Drug Utilization Review (DUR) process which identifies, investigates
More informationSUBOXONE Sublingual Tablets Buprenorphine Hydrochloride + Naloxone Hydrochloride Consumer Medicine Information
Sublingual Tablets Buprenorphine Hydrochloride + Naloxone Hydrochloride What is in this leaflet? This leaflet answers some common questions about. It does not contain all the available information. All
More informationComprehensive Substance Abuse Strategic Action Plan
Report on West Virginia s Comprehensive Substance Abuse Strategic Action Plan SubStance abuse is destroying West Virginia. People throughout the state, from the Northern Panhandle to the southern coalfields,
More information